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Extent of donor engraftment and overall 
survival following haploidentical HCT 
when conditioned with 
radioimmunotherapy and 
cyclophosphamide in murine leukemia 
model. Percent donor engraftment is 
equivalent when mice are conditioned 
with cyclophosphamide paired with 
either radioimmunotherapy or total body 
irradiation in multiple hematopoietic 
lineages, such as (A) T cells and (B) 
myeloid cells. (C) Conditioning mice with 
cyclophosphamide and 
radioimmunotherapy prior to HCT 
significantly increased overall survival 
compared to untreated leukemia bearing 
mice. 
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Hematopoietic cell transplantation (HCT) can provide lasting cures for patients suffering from 
leukemia, lymphoma, and myeloma. In particular, marrow transplants remain the most effective 
therapy for patients with advanced AML. Despite these successes there are many challenges still 
facing successful transplantation. Prior to transplantation the diseased marrow must be completely 
ablated otherwise patients risk chance of cancer recurrence, however, such treatments come at the 
cost of significant toxicity to patients. Common conditioning regimens include toxic chemotherapy 
and total body irradiation. If researchers can target these cytotoxic agents specifically to bone 
marrow, then the cancer cells are exposed to higher drug doses and healthy tissue remains intact. 
Even with the perfect conditioning regimen many patients still face the challenge of finding a 
compatible marrow donor. The compatibility of a donor is determined by human leukocyte antigen 
(HLA) typing. HLAs encode components of the major histocompatibility complex (MHC), and while 
many HLA genes exist only 4 or 5 HLAs are evaluated for transplantation. Most clinical transplant 
centers require a donor to match 7/8 or 9/10 HLA alleles in order to be considered suitable. The 
most likely source for a match is a sibling as each sibling has a 25% chance of inheriting an identical 
complement of HLA alleles. However, 70% of patients fail to find a match within their family and 
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instead rely on the national marrow registry. This is particularly challenging for patients of ethnic 
minorities because their registration rates are lower and show greater attrition. 
With both of these major challenges in mind, doctors and researchers at Fred Hutch and the SCCA 
are exploring radioimmunotherapy as a conditioning regimen for HCT using haploidentical donors in 
a mouse leukemia model. Dr. Johnnie Orozco and colleagues in the Clinical Research Division 
reported their findings in a recent issue of Blood. To better target the conditioning regimen Dr. 
Orozco used an antibody targeting CD45, a cell surface marker commonly expressed in leukemia 
and lymphoma cells. The antibody was conjugated to a radioactive isotope yttrium-90, enabling the 
radiation to be delivered directly to cancer cells, rather than exposing the entire body. To address 
the lack of perfect donor matches these studies were performed in mice where 50% of HLA markers 
are identical between donor and recipient. "We felt it was important to develop this novel 
conditioning approach using haploidentical donors, as not all patients that require a potentially 
curative bone marrow transplant may have a fully matched donor identified. This is especially 
challenging in patients from ethnic minority groups." said Dr. Orozco. 
Conditioning regimens for HCT commonly include total body irradiation and a cytotoxic agent, 
fludarabine. Thus researchers compared the success of HCT engraftment replacing total body 
irradiation with radioimmunotherapy alone or in combination with fludarabine using haploidentical 
donors. Non-leukemic mice were treated with conditioning regimens and then analyzed 28 days later 
for engraftment success. Radioimmunotherapy alone was not sufficient for HCT, however, when 
paired with fludarabine the rate of engraftment was significant (~20%). With radioimmunotherapy 
functioning similar to total body irradiation, researchers also explored cyclophosphamide as an 
alternative to fludarabine. As a chemotherapy cyclophosphamide is similar to fludarabine, yet it 
better suppresses the immune system, which is important in the context of haploidentical donors. 
When analyzed at 28 days, engraftment levels were equivalent when radioimmunotherapy was 
paired with either fludarabine or cyclophosphamide. The researchers chose to move forward with 
cyclophosphamide as it’s immunosuppressive activities were likely to provide long term benefits after 
HCT such as GVHD prophylaxis. 
This combination was then tested in a mouse leukemia model, along with one important change to 
administration. In the initial studies HCT took place three days after conditioning, for the following 
studies this was extended to four days, with the concern that residual radiation could be affecting 
engraftment. This regimen resulted in highly successful HCT. The median survival of mice treated 
this way nearly doubled, and 50% of mice lived more than 200 days (compared to 34 days for 
control mice). Moreover, donor cells represented 80% of the marrow population from 28 days up to 6 
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months and beyond. Researchers also verified that donor cells were the major component of most 
differentiated cell types including T lymphocytes, B lymphocytes, and myeloid cells. 
While these results demonstrate successful HCT using radioimmunotherapy, they did not formally 
test whether the new conditioning regimen reduced toxicity compared to total body irradiation, yet a 
decreased toxicity can be inferred, "we suspect a targeted approach to deliver radiation should be a 
better tolerated compared to total body irradiation. Specifically, mice treated with 
radioimmunotherapy did not experience significant weight loss or morbidity, compared to mice 
treated with total body irradiation. In addition, our targeted approach did not require fludarabine, 
eliminating a source of therapy related toxicity. Previously we have done formal toxicity studies 
evaluating the use of anti-CD45 radioimmunotherapy and found no significant renal or hepatic 
toxicity, but did find transient myelosuppressive effects that resolved within a few weeks, as would 
be expected from targeting CD45 hematopoietic tissues." said Dr. Orozco. 
With these promising results, researchers at Fred Hutch are now exploring alternative radioisotopes 
for radioimmunotherapy. Using higher energy emitting atoms is likely to increase engraftment levels 
closer to 100%. 
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